An interventional study of Acellular Dermal Matrix and Acellular Dermal Matrix with autologous orthobiologics in Rotator Cuff Tears, sponsored by Istituto Ortopedico Rizzoli. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-19.
Sponsored by Istituto Ortopedico Rizzoli · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Rotator Cuff Injuries with a site in Italy — 8 open to participants now, 8 under way, none of them phase 3. Rotator Cuff Injuries · Italy.
Among the 20 studies in Rotator Cuff Injuries with a site in Italy, this one is the 5th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2023, is one of 14 with no phase, and was the 13th registered.
632 studies on the registry are indexed under Rotator Cuff Injuries; 157 are open to participants now.
Browse Rotator Cuff Injuries studies →8 of the 20 studies in Rotator Cuff Injuries with a site in Italy are open now. Recruiting first, the newest first:
Voll Medical Technologies Ltd. · Sites in Italy, Israel
Ages 50+
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 40–70
Smith & Nephew, Inc. · Sites in Italy, United States, Australia and 3 more countries
Ages 18+
Smith & Nephew, Inc. · Sites in Italy, Australia, Germany and 1 more country
Ages 18+
Exactech · Sites in Italy, United States, Canada and 3 more countries
Ages 21+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 100 Rotator Cuff Injuries studies recruiting now, 40 (40%) set no upper age limit and 41 (41%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 72 is above the median of 60 across 456 interventional studies indexed under Rotator Cuff Injuries.
Median enrollment 49 across the 14 interventional studies, 71 across the 6 observational. Of the 10 that completed or were terminated, 3 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 20 have an industry lead sponsor. The 10 most frequent:
Istituto Ortopedico Rizzoli is the lead sponsor of 305 studies on the registry; 104 are open to participants now.
Istituto Ortopedico Rizzoli has 6 studies filed under Rotator Cuff Injuries — fewer than ten, so there is no comparison to draw.
2 of the studies in Rotator Cuff Injuries with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07545707University of MoliseRadiologist-Integrated Finite Element Framework for Acromial Stress in Reverse Shoulder Arthroplasty | 2026-12-10 |
| NCT05444465Smith & Nephew, Inc.Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears | 2027-04-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Rotator Cuff Injuries with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The use of biologic acellular matrices for the surgical augmentation of rotator cuff lesions has greatly expanded inrecent years. The study team patented a method for removing cells from human dermis (Acellular Dermal Matrix), maintaining unaltered biological and structural integrity. Acellular Dermal Matrix has been succesfully used for rotator cuff surgical repair augmentation beside in a limited number of patients. The aim of the project is to demonstrate the therapeutical efficacy of this strategy in patients affected by rotator cuff massive tears. Acellular Dermal Matrix will be also combined with autologous orthobiologics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Enrolled patients will be randomly assigned to the suture-bridge technique with acellular dermal matrix
Other: Acellular Dermal Matrix
Enrolled patients will be randomly assigned to the suture-bridge technique with acellular dermal matrix with orthobiologics autologous: humeral bone marrow concentrate and subacromial bursa
Other: Acellular Dermal Matrix with autologous orthobiologics
Patinets will be treated with acellular dermal matrix with standard arthroscopic technique performed as per normal clinical practice. For the tendon repair the acellular dermal matrix patch will be placed over the repaired tendon with dedicated sutures and anchors.
Patinets will be treated with acellular dermal matrix enriched with autologous humeral bone marrow concentrate and subacromial bursa with standard arthroscopic technique. Humeral bone marrow concentrate will be harvested from the proximal humeral head inthe operating room and concentrated by an automatic close system.
re-tear rate
Presence/absence of re-tear on magnetic resonance imaging
Time frame: 12 months after surgery
cell yeld
number of stromals cells contained in the humeral bone marrow concentrate
Time frame: baseline
subacromial bursa
Half of the subacromial bursal tissue wll be assessed for determining the cell yield (number of stromal cells contained for mg of tissue) and half for histological processing
Time frame: baseline
Ran from Dec 2023 to primary completion in Jul 2025, 19 months.
Of 228 non-industry interventional studies with no phase under Rotator Cuff Injuries, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's 19 months is close to that.
Counting every sponsor, half of 252 studies reached it within 23 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.